Ticker Details
MannKind Corporation MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.
IPO Date:	July 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.04B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 3.01%
Avg Daily Range (30 D):	$0.08 | 2.56%
Avg Daily Range (90 D):	$0.12 | 3.01%

Institutional Daily Volume
Avg Daily Volume:	2.87M
Avg Daily Volume (30 D):	4.95M
Avg Daily Volume (90 D):	4.98M

Trade Size
Avg Trade Size (Sh.):	306
Avg Trade Size (Sh.) (30 D):	236
Avg Trade Size (Sh.) (90 D):	232

Institutional Trades
Total Institutional Trades:	3,950
Avg Institutional Trade:	$1.58M
Avg Institutional Trade (30 D):	$1.56M
Avg Institutional Trade (90 D):	$1.98M
Avg Institutional Trade Volume:	.25M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.89M
Avg Closing Trade (30 D):	$1.79M
Avg Closing Trade (90 D):	$2.32M
Avg Closing Volume:	384.28K

News

May 12, 2026 @ 2:30 PM The $59B Quiet Shift Reshaping How Patients Access... Source: Equity Insider

Mar 18, 2026 @ 2:00 PM A Key "Master" Protein That Declines by Half After... Source: Equity-Insider.Com

Feb 26, 2026 @ 11:19 PM Why MannKind Stock Tumbled on Thursday Source: Eric Volkman

Feb 19, 2026 @ 2:00 PM MannKind to Participate in the Oppenheimer 36th An... Source: Na

Jan 29, 2026 @ 6:31 PM Longevity Biotech Stocks Surge as $27 Trillion Hea... Source: Prnewswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.07	$-.05	$-.05
Diluted EPS	$-.07	$-.05	$-.05
Revenue	$360.78M	$90.17M	$111.96M
Gross Profit	$330.24M	$82.66M	$98.03M
Net Income / Loss	$-23.91M	$-16.62M	$-15.95M
Operating Income / Loss	$14.84M	$-1.67M	$-7.69M
Cost of Revenue	$30.54M	$7.51M	$13.93M
Net Cash Flow	$5.53M	$-22.05M	$-52.51M
PE Ratio

Splits
Mar 03, 2017	1:5